북미 증후군 멀티플렉스 진단 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

북미 증후군 멀티플렉스 진단 시장 – 2029년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • May 2022
  • North America
  • 350 Pages
  • 테이블 수: 61
  • 그림 수: 43

>북미 증후군 멀티플렉스 진단 시장 - 제품 및 서비스(시약 및 소모품, 기기, 소프트웨어 및 액세서리 및 서비스), 감염 유형(바이러스, 박테리아, 기생충 및 진균), 질병( 호흡기 감염, 위장염, 성병, 패혈증, 뇌막염 및 기타), 패널 유형(호흡기 패널, 위장관 패널, 성병 패널, 혈액 패혈증 패널, 뇌막염 패널 및 기타), 최종 사용자(임상 실험실, 병원, 제약 및 생명 공학 회사, 연구소 및 기타) 산업 동향 및 2029년까지의 예측.

북미 증후군 멀티플렉스 진단 시장

시장 정의 및 통찰력

증후군 멀티플렉스 진단은 호흡기 감염, 감염성 위장염 , 성병, 패혈증, 수막염과 같은 감염성 질환을 감지하는 데 사용되는 일종의 고급 진단 검사입니다 . 증후군 멀티플렉스 진단은 또한 임상의 또는 병원이 다양한 유형의 질병의 증상과 징후를 감지하는 데 도움이 됩니다. 이를 통해 의료 서비스 제공자는 환자에게 올바른 치료를 제공하고 보다 정확한 결과와 보다 빠르게 수행할 수 있는 치료를 제공할 수 있습니다.

증후군 멀티플렉스 진단 시장

증후군 멀티플렉스 진단 시장

증후군 멀티플렉스 검사는 여러 병원체를 동시에 진단하는 데 사용됩니다. 증후군 멀티플렉스 진단에서는 다양한 유형의 시약 및 소모품과 기구 및 액세서리가 사용되어 정확성을 유지하고 빠른 진단 결과를 제공합니다. 이러한 멀티플렉스 검사는 특정 감염을 빠르게 진단하여 임상 관리 결정을 신속하게 내릴 수 있습니다. 멀티플렉스 기술에 기반한 검사는 검사 패널이라고 합니다. 증후군 검사에 사용되는 패널은 동일하거나 유사한 증후군 유형과 관련된 여러 질병을 진단하도록 설계되었습니다. 이러한 패널은 치료 시점에서 질병의 원인을 평가하는 데 도움이 됩니다. 위장관 패널과 호흡기 패널은 증후군 패널의 유형입니다.

증후군 멀티플렉스 검사는 멀티플렉스 PCR의 첨단 기술을 활용하여 증후군 멀티플렉스 진단에 사용되는 다중 패널을 사용하여 1시간 이내에 진단 결과를 제공하여 정확하고 빠른 진단 결과를 제공합니다. 새로운 세대의 증후군 멀티플렉스는 호흡기 검체, 혈액 및 뇌척수액에서 일반적인 유형의 병원체를 빠르게 식별할 수 있습니다. 멀티플렉스 패널을 사용하면 처리 시간이 단축되고 불필요한 다른 실험실 검사가 줄어들고 진단이 더 빨라지고 표적 치료가 가능합니다.

Data Bridge Market Research에 따르면 북미 증후군 멀티플렉스 진단 시장이 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 9.0%로 성장할 것으로 분석됩니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020

양적 단위

매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨

다루는 세그먼트

Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others),  Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others),  End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Akonni Biosystems, Inc. (U.S.), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Applied BioCode, Inc. (U.S.), Prominex Inc. (U.S.), Nanomix, Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany)

Syndromic Multiplex Diagnostic Market Dynamics

Drivers

  • Rise in prevalence of infectious diseases

The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.

  • Increase in regulatory approval for acute respiratory syndrome coronavirus testing

In May 2020, biomérieux SA received FDA Emergency Use Authorization (EUA) for the BIOFIRE RP2.1 panel, which is used for the detection of 22 pathogens which is causing respiratory infections, including SARS-CoV-2 for COVID-19 disease.

The regulatory authorities, such as the FDA or CE mark, provide Emergency Use Authorization (EUA) approval for commercializing SARS-CoV-2 panels and testing to detect viruses associated with COVID-19 disease, which is a driver for the growth of the market.

Opportunities

  • Strategic Initiatives taken by market players

In March 2021, F. Hoffman-La Roche Ltd acquired GenMark Diagnostics, a leading multiplex molecular diagnostics provider. This acquisition has helped the company to broaden Roche’s molecular diagnostic portfolio. These strategic initiatives taken by the market players, including focused segment product launches, are helping them expand their global reach and enhance their product portfolio and acting as an opportunity for the market's growth.

  • Introduction of technologically advanced products

The syndromic multiplex testing utilizes the advanced technology of multiplex PCR to detect, isolate, or amplify targeted nucleic acid to provide accurate and fast diagnostic results; the advanced technology provides a diagnostic result within 45 to 60 min.  Hence, the development of technologically advanced products is acting as an opportunity for the market's growth.

Restraint/Challenge

  • High Cost of Diagnostic Products

The multiplex syndromic testing applications utilize the real-time Polymerase chain reaction (PCR), which delivers the results with amplification curves and correct values. The instruments used in the syndromic multiplex diagnostic require high maintenance costs. Hence, the high cost of instruments is a challenge for the market.

Post COVID-19 Impact on Syndromic Multiplex Diagnostic market

COVID-19 has positively affected the market. Market players are launching different products for the detection of the SARS-CoV virus. There is an increase in approval of products by regulatory bodies after post COVID-19, which leads to an increase in market growth.

Recent Development

  • In March 2021, Luminex Corporation. A Diasorin Company received FDA Emergency Use Authorization and CE mark for expanded NxTAG respiratory panel test. This approval has helped the company to increase its revenue.

Syndromic Multiplex Diagnostic Market Scope

The syndromic multiplex diagnostic market is categorized into five segments: product and services, infection type, disease, panels type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Reagents & Consumables
  • Instruments, Software & Accessories
  • Services

Based on products and services, the North America syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services.

Infection Type

  • Viral
  • Bacterial
  • Parasites
  • Fungal

Based on infection type, the North America syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal.

Disease

Based on disease, the North America syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others.

Panels Type

  • Respiratory Panel
  • GI-Enteric Panel
  • Sexually Transmitted Disease Panel
  • Blood-Sepsis Panel
  • Meningitis Panel
  • Others

Based on panels type, the North America syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others.

End User

  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Others

증후군 멀티플렉스 진단 시장

북미 증후군 멀티플렉스 진단 시장은 최종 사용자를 기준으로 임상 실험실, 병원, 제약 및 생명 공학 회사, 연구 기관 등으로 구분됩니다.

증후군 멀티플렉스 진단 시장 지역 분석/통찰력

위에 언급된 대로, 증후군 멀티플렉스 진단 시장을 분석하고 국가, 제품 및 서비스, 감염 유형, 질병, 패널 유형 및 최종 사용자별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

보고서에서 다루는 국가는 미국, 캐나다, 멕시코입니다.

미국의 증후군 멀티플렉스 진단 시장은 감염성 질환의 유병률 증가와 조기 및 정확한 진단에 대한 수요 증가로 인해 성장할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변경 사항을 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

증후군 멀티플렉스 진단 시장 점유율 분석

증후군 멀티플렉스 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 사우디 아라비아의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 증후군 멀티플렉스 진단 시장과 관련된 회사의 초점에만 관련이 있습니다.

북미 증후군 멀티플렉스 진단 시장에서 활동하는 주요 기업으로는 BioFire Diagnostics(bioMérieux SA의 자회사), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid(Danaher의 자회사), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Akonni Biosystems, Inc., Biocartis, QuantuMDx Group Ltd., Applied BioCode, Inc., Prominex Inc., Nanomix, Inc., Curetis(OpGen, Inc.의 자회사) 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT AND SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021)

5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES

6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES

6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING

6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS

6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE

6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS

6.4 CHALLENGES

6.4.1 PRODUCT RECALLS

6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES

7.4 SERVICES

8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE

8.1 OVERVIEW

8.2 VIRAL

8.2.1 CORONAVIRUS

8.2.2 INFLUENZA VIRUS

8.2.3 ADENOVIRUS

8.2.4 RHINOVIRUS

8.2.5 ROTAVIRUS

8.2.6 OTHERS

8.3 BACTERIAL

8.3.1 PNEUMONIAE

8.3.2 BORDETELLA PERTUSSIS

8.3.3 STAPHYLOCOCCUS

8.3.4 OTHERS

8.4 PARASITES

8.5 FUNGAL

9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS

9.3 GASTROENTERITIS

9.4 SEXUALLY TRANSMITTED INFECTIONS

9.5 SEPSIS

9.6 MENINGITIS

9.7 OTHERS

10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE

10.1 OVERVIEW

10.2 RESPIRATORY PANEL

10.3 GI-ENTERIC PANEL

10.4 SEXUALLY TRANSMITTED DISEASE PANEL

10.5 BLOOD-SEPSIS PANEL

10.6 MENINGITIS PANEL

10.7 OTHERS

11 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICAL LABORATORIES

11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.5 RESEARCH INSTITUTES

11.6 OTHERS

12 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION

12.1 NORTH AMERICA

12.1.1 U.S.

12.1.2 CANADA

12.1.3 MEXICO

13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMÉRIEUX SA)

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 F. HOFFMANN-LA ROCHE LTD

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 LUMINEX CORPORATION. A DIASORIN COMPANY

15.3.1 COMPANY SNAPSHOT

15.3.2 RECENT FINANCIALS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.4 CEPHEID (A SUBSIDIARY OF DANAHER)

15.4.1 COMPANY SNAPSHOT

15.4.2 RECENT FINANCIALS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENTS

15.5 QIAGEN

15.5.1 COMPANY SNAPSHOT

15.5.2 RECENT FINANCIALS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENT

15.6 ABBOTT

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENT

15.7 AKONNI BIOSYSTEMS, INC.

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 APPLIED BIOCODE, INC.

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 BD

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 BIOCARTIS

15.10.1 COMPANY SNAPSHOT

15.10.2 REVENUE ANALYSIS

15.10.3 PRODUCT PORTFOLIO

15.10.4 RECENT DEVELOPMENT

15.11 BIO-RAD LABORATORIES, INC.

15.11.1 COMPANY SNAPSHOT

15.11.2 REVENUE ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENT

15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENT

15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.)

15.13.1 COMPANY SNAPSHOT

15.13.2 RECENT FINANCIALS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 HOLOGIC, INC.

15.14.1 COMPANY SNAPSHOT

15.14.2 RECENT FINANCIALS

15.14.3 PRODUCT PORTFOLIO

15.14.4 RECENT DEVELOPMENT

15.15 MIRXES PTE LTD.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 NANŌMIX, INC.

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 PROMINEX INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

15.18 QUANTUMDX GROUP LTD.

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENTS

15.19 SEEGENE INC.

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

15.2 SIEMENS HEALTHCARE GMBH

15.20.1 COMPANY SNAPSHOT

15.20.2 RECENT FINANCIALS

15.20.3 PRODUCT PORTFOLIO

15.20.4 RECENT DEVELOPMENT

15.21 THERMOFISHER SCIENTIFIC INC.

15.21.1 COMPANY SNAPSHOT

15.21.2 RECENT FINANCIALS

15.21.3 PRODUCT PORTFOLIO

15.21.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

표 목록

TABLE 1 COST OF THE PRODUCT

TABLE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 42 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 43 U.S. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 44 U.S. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 45 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 46 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 47 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 49 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 50 CANADA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 51 CANADA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 52 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 53 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 54 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 56 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 57 MEXICO VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 58 MEXICO BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 59 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 60 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 61 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD

FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA

FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE

FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019

FIGURE 18 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021

FIGURE 19 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)

FIGURE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)

FIGURE 21 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE

FIGURE 22 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021

FIGURE 23 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)

FIGURE 24 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)

FIGURE 25 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE

FIGURE 26 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021

FIGURE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)

FIGURE 28 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)

FIGURE 29 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021

FIGURE 31 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)

FIGURE 32 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)

FIGURE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE

FIGURE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021

FIGURE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)

FIGURE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)

FIGURE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)

FIGURE 43 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The North America Syndromic Multiplex Diagnostic Market will grow at a CAGR of 9.0% during the forecast by 2029.
The significant factors flourishing the growth of the North America Syndromic Multiplex Diagnostic Market are Rise in prevalence of infectious diseases, and Increase in regulatory approval for acute respiratory syndrome coronavirus testing.
The major players operating in the North America Syndromic Multiplex Diagnostic Market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Akonni Biosystems, Inc. (U.S.), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Applied BioCode, Inc. (U.S.), Prominex Inc. (U.S.), Nanōmix, Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany).
The major countries covered in the North America Syndromic Multiplex Diagnostic Market are U.S., Canada, and Mexico.